Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
Ticker Information
Ticker
LCTXCompany Name
LINEAGE CELL THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NYSEMKTLINEAGE CELL THERAPEUTICS INC - Free Cash Flow to Debt Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
LCTX - FCF/D Historical data
| Date | Free Cash Flow | Free Cash Flow to Debt | Total Liabilities |
|---|---|---|---|
| 6/30/2025 | $ -23.15M | 0 | $ 43.69M |
| 3/31/2025 | $ -22.82M | 0 | $ 34.1M |
| 12/31/2024 | $ -23.66M | 0 | $ 36.21M |
| 9/30/2024 | $ -23.06M | 0 | $ 31.8M |
| 6/30/2024 | $ -22.33M | 0 | $ 35.93M |
| 3/31/2024 | $ -23.63M | 0 | $ 37.49M |
| 12/31/2023 | $ -29.24M | 0 | $ 39M |
| 9/30/2023 | $ -31.42M | 0 | $ 39.49M |
| 6/30/2023 | $ -32.01M | 0 | $ 40.43M |
| 3/31/2023 | $ -32.64M | 0 | $ 44.19M |
Key Performance Insights, Last 5 Years
- LINEAGE CELL THERAPEUTICS INC's latest trailing twelve months (TTM) FCF/D stands at 0.
- Over the past 5 years, LINEAGE CELL THERAPEUTICS INC's average FCF/D has been 0.06.
- The median FCF/D for LINEAGE CELL THERAPEUTICS INC during this period was 0.06
- LINEAGE CELL THERAPEUTICS INC reached its highest FCF/D over the past 5 years at 0.09.
- The lowest FCF/D recorded by LINEAGE CELL THERAPEUTICS INC in the same timeframe 0.01
Similar metrics to Liabilities:
- Total Liabilities - [Balance Sheet] Total liabilities are the sum of all possible claims against the company. Common examples are [Debt], [Payables], deferred revenues, issued bonds, warranties, and tax liabilities.
- Free Cash Flow - [Calculation] Free Cash Flow is a metric that measures the cash that remains after a company pays its operating expenses [OpEx] and capital expenditures [CapEx]. It can be calculated as Net Cash Flow from Operations [NCFO] minus capital expenditures.
- Current Liabilities - [Balance Sheet] The current (short-term) portion of [Liabilities] includes obligations that are due to be paid to creditors within one year, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
- Price to Free Cash Flow - [Calculation] Measures a company’s [MarketCap] in relation to its Free Cash Flow [FCF].
- Non-Current Liabilities - [Balance Sheet] The non-current (long-term) portion of [Liabilities] includes obligations that are due to be paid to creditors more than year in the future, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
Definition of Free Cash Flow to Debt
[Calculation] The Free Cash Flow to Debt ratio allows investors to judge a company’s financial stability. It represents the fraction of debt that could be repaid within one year if all of the free cash flow would be used to repay debt. It is calculated by dividing Free Cash Flow [FCF] by a company’s [Liabilities].FCF / Liabilities
(=) FCF/D FCF/D for LINEAGE CELL THERAPEUTICS INC is calculated as follows: FCF [ $ -19.58M ] / Liabilities [ $ 12.91M ]
(=) FCF/D [ 0 ] LCTX - Free Cash Flow to Debt, Last 5 years
0.01
Minimum
Dec 31, 2022
0.09
Maximum
Mar 31, 2022
0.06
Average
0.06
Median
FCF/D Benchmark AnalysisMarket
The chart above depicts the distribution of FCF/D for companies in the Total Stock Market. The average FCF/D of the companies is 0.11 with a standard deviation of 0.1.
The following table provides additional summary stats:
FCF/D in the Market:
| filtered constituents | 2.25K |
|---|---|
| min | 0 |
| max | 0.47 |
| average | 0.11 |
| median | 0.09 |
| std | 0.1 |